Sensus Healthcare
RELATED CONTENT
April 1, 2014 — Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognized Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two low-energy X-ray devices, SRT-100 and SRT-100 Vision.
April 01, 2014 
Sensus Healthcare has announced its newest introduction for non-melanoma skin cancer treatment at the 55th annual American Society of Therapeutic Radiation Oncology (ASTRO) in Atlanta, Ga. Sensus has an advanced SRT-100 superficial radiotherapy platform, featuring SharpBeam and has introduced the recently FDA-cleared technology that now allows you to "See what you Treat."
September 25, 2013 
Sensus Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) to treat Keloids with the SRT-100. The SRT-100 is an alternative to surgery in treating non-melanoma skin cancer and now is approved to treat keloids caused by surgery or injury. Leading dermatologists and oncologists have found the SRT-100 superficial radiotherapy system to be a choice for their patients who are not good surgical candidates. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers and keloids in hospitals and private practice settings.
May 28, 2013 August 15, 2012 — Mission Search Corp., a Tampa, Fla.-based healthcare search and staffing organization, announced it has joined with Sensus Healthcare to provide commissioning services to Sensus’ clientele.
August 15, 2012